Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Michael D Radmacher, et al.
Blood Advances|January 4, 2018
Direct evidence for a polygenic etiology in familial multiple myelomaBritt-Marie Halvarsson, Anna-Karin Wihlborg, Mina Ali, et al.
The New England Journal of Medicine|May 3, 2008
MicroRNA expression in cytogenetically normal acute myeloid leukemiaGuido Marcucci, Michael D Radmacher, Kati Maharry, et al.
British Journal of Haematology|October 11, 2014
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk diseaseKlaus M Kortüm, Christian Langer, Jorge Monge, et al.
The Journal of Allergy and Clinical Immunology|December 15, 2015
IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migrationUpasana Kulkarni, Christian M Karsten, Thomas Kohler, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Nature Medicine|June 14, 2016
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicityRuth Eichner, Michael Heider, Vanesa Fernández-Sáiz, et al.
British Journal of Haematology|September 30, 2017
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trialHermann Einsele, Monika Engelhardt, Christoph Tapprich, et al.
European Journal of Haematology|March 8, 2020
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myelomaAlessandra Di Bacco, Nizar J Bahlis, Nikhil C Munshi, et al.
Blood|October 22, 2017
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patientsHervé Avet-Loiseau, Nizar J Bahlis, Wee-Joo Chng, et al.
Pageof 8